Evusheld

(Note 2)

Tixagevimab (genetical recombination) and cilgavimab (genetical recombination)

Approval Information

Brand NameEvusheld

Generic NameTixagevimab (genetical recombination) and cilgavimab (genetical recombination)

ApprovedAugust 2022

Type(Note 2)

Review Reports

English Review Report

PDF · 1.44 MB

Japanese Review Report

PDF · 2.57 MB

Want structured data, translation summaries & alerts?

PharmaLens is building the most comprehensive English-language PMDA intelligence platform. Join the waitlist for early access.

Join the Waitlist

Source: PMDA Website. Review reports are provided under Japan's Public Data License v1.0. Translations and structured data by PharmaLens are unofficial and for reference only.

← Back to Drug Database